Amicus Therapeutics Brings Relief in Management of Rare Conditions

Amicus Therapeutics is a medical-pharmaceutical distributing medical supply to patients with rare medical conditions and disorders. Most of which are either epidermolysis bullosa, a stubborn skin disorder basically genetically passed on, lysosomal conditions, Pompe and Fabry among their main focus. Ordinarily, there is scarce of information in regards to the risk factors, scanty treatment options, and management.

Scientists, researcher alongside Amicus Therapeutics have pulled hands to ensure the areas get explored for latter better disease management. The Michael J. Fox Foundation made a generous donation of $500,000 to help the advancement of studies and aid research work. This was possible in collaboration with the School of Medicine, David Geffen Faculty of Medicine. Similarly, Alzheimer’s Drug Discovery contributed toward such a course with $210,300 which brought positive progress in the clinical management of these rarity diseases through UCLA. Learn more about Amicus Therapeutics at Dial Dish.

Another development has been on Chaperone-Advanced Replacement Therapy (CHART™) which is an enzyme replacement therapy suitable for individualized forms of treatment. It has also been in co-operation and partnership with GlaxoSmithKline and JCR pharmaceuticals especially in contracts regarding the sale of drugs. Amicus Therapeutics is finalizing on the development and commercialization of Migalastat.

Read: https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo

About Amicus Therapeutics

Amicus Therapeutics is a pharmaceutical company with a different approach in medicine and drug development which explains its popularity. It was established in 2002 in New Jersey but currently with an office in San Diego. It has grown its stocks to participate in publicly traded stocks. It uses the symbol NASDAQ – FLOD since 2007 when it was acquired these rights.

It enjoys a pool of composed and professionals with expertise in their executive leadership. John Crowley and Bradley Campbell lead the team as the CEO and COO respectively. The company has enjoyed the benefits of the good network from a donor, funders (Radius ventures and Canaan Partners), researchers and customers. It recently merged with Scioderm Pharmaceuticals which naturally increased Amicus Therapeutics’ valuation and net worth. Read more at GcReport.com about Amicus Therapeutics.